Roivant Sciences Ltd. (ROIV)
- Previous Close
11.18 - Open
11.27 - Bid 11.17 x 1200
- Ask 11.26 x 100
- Day's Range
11.19 - 11.30 - 52 Week Range
8.24 - 13.24 - Volume
530,394 - Avg. Volume
6,820,345 - Market Cap (intraday)
9.025B - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
2.13 - EPS (TTM)
5.27 - Earnings Date Jun 26, 2024 - Jul 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.90
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
roivant.comRecent News: ROIV
Performance Overview: ROIV
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ROIV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ROIV
Valuation Measures
Market Cap
9.01B
Enterprise Value
2.85B
Trailing P/E
2.12
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
72.91
Price/Book (mrq)
1.48
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
3,624.14%
Return on Assets (ttm)
-13.77%
Return on Equity (ttm)
105.80%
Revenue (ttm)
123.24M
Net Income Avi to Common (ttm)
4.35B
Diluted EPS (ttm)
5.27
Balance Sheet and Cash Flow
Total Cash (mrq)
6.67B
Total Debt/Equity (mrq)
7.69%
Levered Free Cash Flow (ttm)
-502.47M
Research Analysis: ROIV
Company Insights: ROIV
ROIV does not have Company Insights